Is Celgene Now a Value Stock?
Biotech drug company Celgene (CELG) has lost around half its value since last Fall. At this point, is the stock a good value?
Biotech drug company Celgene (CELG) has lost around half its value since last Fall. At this point, is the stock a good value?
All the recent news on Celgene (CELG) has been bad lately, But profits are expected to climb 14% this year and the stock has a P/E of just 11. So is the stock a good buy or goodbye?
Celgens (CELG) sank 20% after the company reported last qtr’s profits, and lowered long-term profit targets. There’s multiple issues going on here, but the stock is now cheap with a P/E of 12.
Biotech stocks were breaking out today — big time. Will that be enough to push shares of Celgene (CELG) out of its two year base? Let’s take a look.
Shares of Celgene (CELG) broke out to a new 52-week high yesterday on high volume as the Biotech sector roared higher — and broke out as well.
Celgene (CELG) and the Biotech sector are both on the verge of breaking out to new highs. But does CELG have what it takes to power higher?
Celgene (CELG) is having another banner year with profits expected to climb 26% this year. But like many growth stocks, CELG is stuck in neutral.
With multiple drugs expected to go through Phase III in the next two years, Celgene (CELG) is expected to grow profits 20% a year regardless of who is elected President.
Shares of Celgene (CELG) aren’t doing much, but the Biotech has a lot going for it, and isn’t getting the respect it deserves.
Celgene (CELG) is down around 20% from a year ago as the Biotechs have been weak. But with risk comes opportunity, and now CELG has 35% upside to my Fair Value.
Celgene (CELG) popped after it settled a patent case regarding Revlimid, and the stock is looking good for the long term.
Celgene (CELG) buys Receptos, and investors send CELG stock to a new All Time High. Here’s why.
Analysts forecast Celgene (CELG) will have strong profit growth in 2016. But is it 30% or 40%?
Celgene’s (CELG) management has a target of $12.50 in EPS by 2020. Here’s what that means for CELG.
I think 2015 will be a year where money flows away from big internet names and into Celgene (CELG).
Shares of Celgene (CELG) Just broke out, are on their way to $100, and I think CELG’s worth $132 in 2015.
Shares of Celgene (CELG) might be resting at the moment, but this stock is a sleeping giant ready to wake.
Biotech stocks like Celgene (CELG) are the rage these days, and CELG is one of the steadiest of the bunch.
I bought Celgene (CELG) last year for $69. Now after it’s more than doubled there is still a bright future ahead — especially in 2015.
Celgene (CELG) had a sizable increase in earnings estimates, and is well on track to make a whopping $10 in 2015.
Celgene (CELG) has been one of the best large cap stocks to own this year. But now CELG’s almost doubled. I think its time to take profits and sell half.
Celgene (CELG) is in the midst of a solid move higher pushed by good profit growth and a still undervalued stock.
Celgene (CELG) is one of the most under appreciated stocks in the stock market. This stock has it all — profit growth, low PE, and momentum.
Shares of Celgene (CELG) have been trending higher as of late. Backed by an all-green one-year chart, the trend is your friend.
Celgene (CELG) has turned back up so I will add it to the Aggressive Growth Portfolio and Growth Portfolio and will sell Body Central (BODY).